Ophthalmic composition

Abstract

To provide an ophthalmic composition having an improved scent-lingering property in which content reduction of terpenoids in the ophthalmic composition is suppressed.SOLUTION: An ophthalmic composition containing (A) at least one selected from the group consisting of polysaccharides; monosaccharides; vitamins; oils; surfactants; anti-allergic components; preservative components; thickening components; polyhydric alcohols; anti-inflammatory components; decongestant components; antioxidant components; and antibacterial components, and (B) terpenoids is housed in a container in which the surface in contact with the ophthalmic composition is partly or wholly formed of a resin containing polybutylene terephthalate. This structure can provide an ophthalmic composition in which content reduction of terpenoids is suppressed.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to an ophthalmic composition and an effect of suppressing a decrease in the content of terpenoids in the ophthalmic composition. A method for imparting an odor suppressing effect to an ophthalmic composition, a method for imparting an odor suppressing effect to an ophthalmic composition, and a method for imparting an odor sustaining agent do. [Background technology]

[0002] Ophthalmic compositions contain menthol, camphor, and the like for the purpose of imparting a sensation of coolness, etc. Terpenoids may be blended. Such ophthalmic compositions are placed in a resin container. Terpenoids in ophthalmic compositions may be stored in a container and then commercialized. It is known that the content decreases over time.

[0003] Among the various types of resins, polyester resins are used as containers for ophthalmic compositions containing terpenoids. Terpenoids are often used in containers because they are fat-soluble. The material was placed in a container containing absorbent polyester resin, polycarbonate resin, etc. A liquid formulation is known (Patent Document 1).

[0004] In addition, in order to prevent a decrease in the content of terpenoids, polyolefin, saturated polyester, etc. The container is made of plastic materials such as polycarbonate and contains oil and surfactants. An oil-in-water emulsion in which the above-mentioned is formed is known (Patent Document 2). [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2002-68963 A [Patent Document 2] Patent No. 4438908 Summary of the Invention [Problem to be solved by the invention]

[0006] However, it is still not sufficient to prevent the decrease in the content of terpenoids in ophthalmic compositions. Instead, further improvements are required. [Means for solving the problem]

[0007] In view of the above problems, the present inventors have conducted extensive research and have found that a specific polysaccharide, vitamin, oil, etc. , surfactants, anti-allergic ingredients, preservatives, thickening ingredients, polyhydric alcohols, anti-inflammatory ingredients, filling ingredients A blood removing component, an antioxidant component and / or an antibacterial component, and a terpenoid are added to an ophthalmic composition. and further comprising at least a part of a surface that comes into contact with the ophthalmic composition, the surface being made of polybutylene terephthalate. By storing it in a container containing polybutadiene (hereinafter also referred to as PBT) resin, Therefore, it was found that the decrease in the content of terpenoids can be suppressed, and the present invention was completed. I did.

[0008] That is, the present invention provides [1] (A) Polysaccharides; Monosaccharides; Vitamin B 12 Vitamin B1, Vitamin A, and Vitamin B1+ one or more vitamins selected from the group consisting of vitamins, vegetable oils, animal oils, and mineral oils; One or more oils selected from the group consisting of polyoxyethylene castor oil, ... Diethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, and One or more surfactants selected from the group consisting of polyoxyl stearates; Tranilas 1 selected from the group consisting of tafen, ketotifen, diphenhydramine, and salts thereof Contains more than 100 types of anti-allergic ingredients; chlorhexidine, sorbic acid, polyhexamethylene biguanide one or more preservative ingredients selected from the group consisting of carboxymethyl The group consisting of cellulose, methylcellulose, vinyl polymer compounds, and salts thereof One or more thickening ingredients selected from the above; polyhydric alcohol; berberine, azulene sulfonic acid , allantoin, zinc sulfate, pranoprofen, and salts thereof. one or more anti-inflammatory ingredients; a decongestant ingredient which is naphazoline and / or its salts; and sulfamethoxazole and / or or a salt thereof; and (B) one or more selected from the group consisting of terpenes. An ophthalmic composition comprising an amide, A part or the whole of the surface that comes into contact with the ophthalmic composition contains polybutylene terephthalate. An ophthalmic composition contained in a container molded from a resin; [2] Among the above-mentioned components (A), the polysaccharides are alginic acid, gellan gum, hyaluronic acid, chondroitin, one or more selected from the group consisting of isotonic acid sulfate and salts thereof; Vitamins include cyanocobalamin, retinol, panthenol, flavin adenine diphosphate One or more selected from the group consisting of oleotides, and their salts; One or more selected from the group consisting of oil, lanolin, petrolatum, and liquid paraffin; The viscosity components are carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone, and calcium. one or more selected from the group consisting of carboxyvinyl polymers and salts thereof; Cole is propylene glycol, glycerin, mannitol, sorbitol, and chitosan. The ophthalmic composition according to [1], wherein the ophthalmic composition comprises one or more compounds selected from the group consisting of silitol; [3] The ophthalmic composition according to item [1] or [2], further comprising sodium edetate; [4] The ophthalmic composition comprises: (A) polysaccharides; monosaccharides; vitamin B 12 Vitamin B1, Vitamin B2, Vitamin one or more vitamins selected from the group consisting of vitamin A, vitamin B12, and panthenol; vegetable oil one or more oils selected from the group consisting of animal oils, and mineral oils; polyoxyethylene Castor oil, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, and one or more interfacial active agents selected from the group consisting of polyoxyl stearate Active agents: Tranilast, ketotifen, diphenhydramine, and their salts One or more anti-allergic ingredients selected from the group consisting of chlorhexidine, sorbic acid, polyhe One or more preservatives selected from the group consisting of hexamethylene biguanide and salts thereof. Carboxymethyl cellulose, methyl cellulose, vinyl polymer compounds, and the like one or more thickening components selected from the group consisting of salts thereof; polyhydric alcohols; berberine, From azulene sulfonic acid, allantoin, zinc sulfate, pranoprofen and their salts one or more anti-inflammatory ingredients selected from the group consisting of naphazoline and / or its salts; Blood removal component; antioxidant component which is dibutylhydroxytoluene; and sulfamethoxa an antibacterial component which is an azole and / or a salt thereof; and (B) a terpenoid is present on the ophthalmic composition, and a part or the whole of the surface that comes into contact with the ophthalmic composition is made of a poly The ophthalmic solution is contained in a container molded from a resin containing butylene terephthalate. A method for imparting an effect of inhibiting a decrease in the content of terpenoids in a composition for use; [5] The ophthalmic composition comprises: (A) polysaccharides; monosaccharides; vitamin B 12 Vitamin B1, Vitamin B2, Vitamin one or more vitamins selected from the group consisting of vitamin A, vitamin B12, and panthenol; vegetable oil one or more oils selected from the group consisting of animal oils, and mineral oils; polyoxyethylene Castor oil, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, and one or more interfacial active agents selected from the group consisting of polyoxyl stearate Active agents: Tranilast, ketotifen, diphenhydramine, and their salts One or more anti-allergic ingredients selected from the group consisting of chlorhexidine, sorbic acid, polyhe One or more preservatives selected from the group consisting of hexamethylene biguanide and salts thereof. Carboxymethyl cellulose, methyl cellulose, vinyl polymer compounds, and the like one or more thickening components selected from the group consisting of salts thereof; polyhydric alcohols; berberine, Azulene sulfonic acid, allantoin, zinc sulfate, pranoprofen, and their salts one or more anti-inflammatory ingredients selected from the group consisting of naphazoline and / or its salts Decongestant; antioxidant, dibutylhydroxytoluene; and sulfamethoxazole. an antibacterial component which is Sasol and / or a salt thereof; and and (B) a terpenoid, and a part or the whole of the surface that comes into contact with the ophthalmic composition is made of polypropylene. By storing the eye drops in a container made of a resin containing butylene terephthalate, the eye drops can be A method for imparting an odor-suppressing effect to a pharmaceutical composition; [6] The solution is contained in an ophthalmic polybutylene terephthalate-containing resin container, and is composed of (A) polysaccharides; monosaccharides; Vitamin B 12 From the group consisting of vitamin B1, vitamin B2, vitamin A, and panthenol one or more vitamins selected from the group consisting of vegetable oils, animal oils, and mineral oils; One or more oils that can be used in the manufacture of cosmetics; polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, Polyoxyethylene polyoxypropylene glycol, and polyoxyl stearate one or more surfactants selected from the group consisting of tranilast, ketotifen, diphen one or more antiallergic ingredients selected from the group consisting of benzodiazepine and salts thereof chlorhexidine, sorbic acid, polyhexamethylene biguanide, and their salts one or more preservative components selected from the group consisting of carboxymethylcellulose, methylcellulose, One or more selected from the group consisting of cellulose, vinyl polymer compounds, and salts thereof. Thickening ingredients: polyhydric alcohol; berberine, azulene sulfonic acid, allantoin, zinc sulfate , pranoprofen, and one or more anti-inflammatory ingredients selected from the group consisting of salts thereof; Decongestant ingredient is naphazoline and / or its salts; dibutylhydroxytoluene an antioxidant component; and an antibacterial component which is sulfamethoxazole and / or its salts. and (B) a terpenoid-containing aromatic compound having a high aromaticity. A follow-up agent; Effect of the Invention

[0009] According to the present invention, it is possible to suppress a decrease in the content of terpenoids in an ophthalmic composition. In addition, the ophthalmic composition containing terpenoids has an inhibitory effect on the decrease in the content of terpenoids. It is possible to provide a method for providing a function.

[0010] The ophthalmic composition, the method for inhibiting a decrease in the content of terpenoids, and the production method of the present invention will be described later. Any suitable ingredients and concentrations may be used. [Brief description of the drawings]

[0011] [Figure 1] 1 is a graph showing the remaining rate of 1-menthol before and after a PBT-containing resin piece is immersed in an ophthalmic composition and subjected to heat treatment. [Diagram 2] 1 is a graph showing the remaining rate of 1-menthol before and after a PBT-containing resin piece is immersed in an ophthalmic composition and subjected to heat treatment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] In the present invention, w / v refers to the weight ratio to the total volume. w / v% is g / It is synonymous with 100 mL. In the present invention, the term "amount blended" is synonymous with the term "content."

[0013] The present inventors have found that when an ophthalmic composition stored in a container contains terpenoids, the ophthalmic composition can be used without any problems during storage. It has been newly discovered that the sensory properties of terpenoids can be lost during the extraction process, resulting in the generation of an unpleasant odor. The ophthalmic composition of the present invention solves such problems and provides a method for treating ophthalmic disorders after use or storage of the ophthalmic composition. It is expected that the deterioration of the fragrance of the ophthalmic composition after use or storage can be suppressed. It is hoped that this can be suppressed.

[0014] The ophthalmic composition of the present invention comprises: (A) polysaccharides; monosaccharides; vitamin B 12 Vitamin B2 , one or more vitamins selected from the group consisting of vitamin A, and panthenol; One or more oils selected from the group consisting of vegetable oils, animal oils, and mineral oils; polyoxyethylene Polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene One or more selected from the group consisting of pyrene glycol and polyoxyl stearate Surfactants such as tranilast, ketotifen, diphenhydramine, and their salts one or more antiallergic ingredients selected from the group consisting of chlorhexidine, sorbic acid, One or more selected from the group consisting of polyhexamethylene biguanide and salts thereof Preservative ingredients: carboxymethylcellulose, methylcellulose, vinyl polymer compounds, and and their salts; polyhydric alcohols; velvet; Phosphorus, azulene sulfonic acid, allantoin, zinc sulfate, pranoprofen, and one or more anti-inflammatory ingredients selected from the group consisting of naphazoline and / or its salts; a decongestant component which is dibutylhydroxytoluene; an antioxidant component which is sulfa One or more selected from the group consisting of an antibacterial component which is methoxazole and / or a salt thereof; Above, as well as The ophthalmic composition of the present invention contains (B) terpenoids. At least a part or all of the surface that comes into contact with the body is contained in a container molded from a resin containing PBT. It is tolerated.

[0015] In the present invention, the ophthalmic composition includes eye drops (same meaning as eye drops or eye drops), contact lenses, etc. Eye drops for lenses, artificial tears, eyewash (synonymous with eyewash or eyewash), contact lens wear Contact lens care products (including disinfectants, preservatives, cleaners, etc.), eye ointments, etc. Any family-related composition is shown.

[0016] In the present invention, these components (A) can be used alone or in combination of two or more. (A) Ingredients may be either naturally occurring or chemically synthesized. It is possible to use commercially available products for each of the components (A).

[0017] In the present invention, the polysaccharide of component (A) is a general term for a polymer in which multiple monosaccharides are bonded together. In the present invention, polysaccharides include polysaccharides that exist in nature and polysaccharides that can be chemically synthesized. Although not limited thereto, the polysaccharide is preferably an acidic polysaccharide.

[0018] The term "acidic polysaccharides" refers to polysaccharides that contain an acidic group. In particular, the repeating unit is a carboxyl group or a sulfate group, but is not limited thereto. The moiety may be, but is not limited to, glucuronic acid, iduronic acid, mannuronic acid, guluronic acid, and the like. Rhodium, amino sugars such as galactosamine and glucosamine, galactose, mannose, Examples include coase and rhamnose.

[0019] Such acidic polysaccharides include, but are not limited to, gellan gum, fucoidan, uroguan, and the like. acid, hyaluronic acid, chondroitin sulfate, alginic acid, dermatan sulfate, heparin, Examples include paran sulfate, keratan sulfate, and salts thereof. However, gellan gum, hyaluronic acid, chondroitin sulfate, alginic acid, and and their salts.

[0020] The polysaccharides of component (A) are either naturally occurring or chemically synthesized. The polysaccharide of component (A) may be any commercially available product. Alkaline metal salts such as sodium and potassium, calcium, magnesium, etc. Alkaline earth metal salts such as sodium, metal salts such as iron and manganese, and other physiological or pharmaceutical The compound may also be used in the form of a physiologically acceptable salt. The potassium metal salt is preferable, and the sodium salt is particularly preferable. These polysaccharides can be used alone or in combination. From the viewpoint of effectively suppressing the decrease in the content of terpenoids, the polysaccharide of component (A) Examples include gellan gum, alginic acid, alkali metal salts of alginic acid, and chondroitin sulfate. Preferred are alkali metal salts of hyaluronic acid, particularly chondroitin sulfate. Sodium hyaluronate and sodium hyaluronate are preferred.

[0021] The molecular weight of the polysaccharide of component (A) varies depending on the number of repeating units and the type, and there is no limit. The weight average molecular weight of the terpenoids is not necessarily limited, but may be in the hundreds to millions. From the viewpoint of more significantly exhibiting the effects of the present invention, such as effectively suppressing the decrease in the viscosity of the resin, the component (A) The molecular weight of the polysaccharide is preferably 1,000 to 5,000,000 in terms of weight average molecular weight. More specifically, for example, The weight-average molecular weight of droitin sulfate or a salt thereof is preferably 1,000 to 3,000,000. More preferably, it is 5,000 to 1.5 million, and even more preferably 10,000 to 500,000. More specifically, for example, the weight average molecular weight of hyaluronic acid or a salt thereof is 100,000 to 50 It is preferable that the number of the ions is 500,000 to 4,000,000, and more preferable that the number of the ions is 600,000 to 25,000,000. It is even more preferable that it be 0 million.

[0022] In the present invention, the monosaccharides of component (A) include glucose, ribose, erythritol, and the like. In addition to aldose such as trose, xylose, arabinose, mannose, and galactose, Also included are ketoses such as ribose, psicose, fructose, sorbose and tagatose. These monosaccharides can be used in either the d-, l- or dl-form. From the viewpoint of effectively suppressing the decrease in the content of lupenoids, the monosaccharide of component (A) is Preferred are glucose, galactose, mannose, and fructose, and particularly preferred are glucose, These monosaccharides may be used alone or in combination of two or more. All of these monosaccharides can be commercially available.

[0023] In the present invention, the vitamins of the component (A) are water-soluble vitamins as long as the effects of the present invention are achieved. The vitamin may be either a fatty soluble vitamin or a vitamin that is soluble in water.

[0024] The vitamins of the component (A) are not specifically limited, but examples of fat-soluble vitamins include , e.g., retinol, retinol acetate, retinol palmitate, retinal, retino Retinoic acid, methyl retinoate, ethyl retinoate, retinol retinoate, vitamin A fatty acid ester, d-δ-tocopheryl retinoate, α-tocopheryl retinoate , β-tocopheryl retinoate, carotene, dehydroretinal, lycopene, and The water-soluble vitamin A salts thereof may be one or more selected from the group consisting of vitamin A salts thereof. Examples of the flavin include riboflavin, flavin mononucleotide, and flavin adenine dinucleotide. Creotide, Riboflavin Butyrate, Riboflavin Tetrabutyrate, Riboflavin sodium 5'-phosphate, riboflavin tetranicotinate, and Vitamin B2 salts such as cyanocobalamin, hydroxocobalamin, methylcobalamin Vitamin B12, such as adenosylcholinesterase, deoxyadenosylcobalamin, and their salts 12 and pantothenyl alcohol (panthenol); do.

[0025] In order to more significantly exhibit the effects of the present invention, the vitamins of the component (A) are particularly Cyanocobalamin, retinol, panthenol, flavin adenine dinucleotide, and and salts thereof. Retinol, Retinol Palmitate, Retinol Acetate, Panthenol, Flavin Adenine Diphosphate It is particularly preferable that the vitamin E be one or more selected from the group consisting of vitamin E, vitamin B12, vitamin B2, vitamin B12, vitamin B12, vitamin B2 ...12, vitamin B As an example of vitamin A, for example, DSM Co., Ltd. Examples of retinol palmitate include IU and the like. The international unit calculated by the method described in the Vitamin A Assay Method in the Sixth Revised Japanese Pharmacopoeia, etc. These vitamins may be used alone or in combination of two or more. These vitamins are all available commercially.

[0026] In the present invention, the oil component of the (A) component is selected from the group consisting of vegetable oils, animal oils, and mineral oils. When an oil is used as component (A), the present invention can use one or more selected oils. From the viewpoint of exhibiting the effect more significantly, vegetable oils and / or mineral oils are more preferred.

[0027] Here, the vegetable oil is not particularly limited as long as it is oil made from plants, and may be a derivative thereof. The vegetable oil of component (A) may contain triglycerides. Specifically, the oils include, but are not limited to, sesame oil, castor oil, soybean oil, peanut oil, almond oil, etc. Oil, wheat germ oil, camellia oil, corn oil, rapeseed oil, sunflower oil, cottonseed oil, olive oil or their derivatives. Effectively suppresses the decrease in terpenoid content From these viewpoints, the vegetable oil of component (A) is preferably sesame oil, castor oil, soybean oil or any of these. Derivatives of these vegetable oils are preferred, and sesame oil and castor oil are particularly preferred. These vegetable oils may be used alone or in combination of two or more. These may also be commercially available.

[0028] In the present invention, the animal oil of component (A) is not particularly limited as long as it is an oil made from an animal. The animal oil of component (A) may be, but is not limited to, squalane ... Orchid, lanolin, orange roughy oil, horse oil, whale oil, liver oil, mink oil, egg yolk oil, beef tallow, milk Examples of the animal oils in component (A) include squalane, refined lanolin, egg Yellow oil or its derivatives are preferred, particularly squalane and refined lanolin. These animal oils can be used alone or in combination of two or more. Any of these animal oils can be commercially available.

[0029] In the present invention, the mineral oil of component (A) is a natural hydrocarbon oil derived from petroleum and is refined. The mineral oil of component (A) specifically refers to the liquid and grease-like chemical substances obtained by the above process. Examples of suitable oils include, but are not limited to, paraffin oil, liquid paraffin, and petrolatum. From the viewpoint of effectively suppressing the decrease in the content of acetaldehyde, liquid paraffin, light liquid paraffin, etc. These mineral oils may be used alone or in combination of two or more. Any of these mineral oils may be commercially available.

[0030] In the present invention, the surfactant of component (A) is polyoxyethylene castor oil, ... Diethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, and The polyoxyl stearates may be at least one selected from the group consisting of polyoxyl stearates.

[0031] Specific examples of such surfactants include poloxamer 407, polyoxyethylene (2 00) Polyoxypropylene (70) glycol, poloxamer 188, polyoxyethylene (1 20) Polyoxypropylene (40) glycol, polyoxyethylene (54) polyoxypropylene Pyrene (39) glycol, polyoxyethylene (20) polyoxypropylene (20) glycol polyoxyethylene polyoxypropylene glycols such as polyoxyethylene glycol and Tetronic; Polyoxyethylene hydrogenated castor oil 5, Polyoxyethylene hydrogenated castor oil 10, Polyoxyethylene hard Hydrogenated castor oil 20, Polyoxyethylene hydrogenated castor oil 40, Polyoxyethylene hydrogenated castor oil 50 Polyoxyethylene hydrogenated castor oil 60, polyoxyethylene hydrogenated castor oil 100, etc. Polyoxyethylene hydrogenated castor oil; Polyoxyethylene castor oil 3, Polyoxyethylene castor Oil 4, Polyoxyethylene Castor Oil 6, Polyoxyethylene Castor Oil 7, Polyoxyethylene Len castor oil 10, polyoxyethylene castor oil 13.5, polyoxyethylene castor oil 17, Polyoxyethylene castor oil 20, Polyoxyethylene castor oil 25, Polyoxy Ethylene castor oil 35, Polyoxyethylene castor oil 40, Polyoxyethylene castor oil Polyoxyethylene castor oil such as polyoxyethylene castor oil 50, polyoxyethylene castor oil 60; stearic acid Polyoxyl 40, stearate polyoxyl 140, etc. The numbers in parentheses indicate the average number of moles added.

[0032] Among these surfactants, poloxamer 407, polyoxyethylene (200) poly Polyoxypropylene (70) glycol, polyoxyethylene hydrogenated castor oil 40, polyoxy Ethylene hydrogenated castor oil 60, Polyoxyethylene castor oil 3, Polyoxyethylene castor oil 10, Polyoxyethylene Castor Oil 35, Polyoxyl Stearate 40, Stearic Acid Polyoxyl 140 is preferred, Poloxamer 407, Polyoxyethylene hydrogenated castor oil 60 , Polyoxyethylene castor oil 10, Polyoxyethylene castor oil 35, Poly stearate Polyoxyl 40 is more preferred. Polyoxyethylene castor oil is castor oil with ethylene oxide. It is a compound formed by addition polymerization of ethylene oxide, and various compounds are known depending on the average number of moles of ethylene oxide added. (A) The ethylene oxide content of the polyoxyethylene castor oil used as component The average number of moles added is not particularly limited, but may be, for example, 2 to 70 moles, and is preferably It is preferably 2 to 60, more preferably 3 to 50, and particularly preferably 3 to 40. The polyoxyethylene polyoxypropylene glycol used as component (A) is The average number of moles of ethylene oxide added in the copolymer is not particularly limited, but may be, for example, 10 to 350 moles. The range is preferably 30 to 300, more preferably 50 to 300, and particularly preferably 50 to 300. Preferably, it can be 100 to 250. The average number of moles of propylene oxide added to propylene glycol is not particularly limited. For example, For example, the amount may be 1 to 130 moles, preferably 5 to 120 moles, and more preferably 10 to 130 moles. The range of the component (A) used may be from 10 to 100, and particularly preferably from 10 to 80. The average number of moles of ethylene oxide added to polyoxyethylene hydrogenated castor oil is not particularly limited. However, the amount may be 3 to 120 moles, preferably 20 to 100 moles, and more preferably 3 to 120 moles. The polyoxyl stearate used as component (A) can be 0 to 80. The average number of moles of ethylene oxide added is not particularly limited, but may be 3 to 200 moles. It is possible to set the value within a range of 20 to 180, preferably within a range of 30 to 160.

[0033] In the present invention, the component (A) is tranilast, ketotifen, diphenhydramine, and salts thereof. Among these, tranilast, ketotifen fumarate, and diphenhydramine hydrochloride are particularly preferred. stomach.

[0034] In the present invention, component (A) is chlorhexidine, sorbic acid, polyhexamethylene The preservative may be one or more preservative ingredients selected from the group consisting of biguanides and their salts. Among the ingredients, chlorhexidine gluconate, sorbic acid, potassium sorbate, polyhe Hexamethylene biguanide is preferred.

[0035] In the present invention, the thickening component (A) may be a cellulose-based polymer compound or a vinyl-based polymer compound. The cellulose-based polymer compound may be, but is not limited to, For example, carboxymethylcellulose, methylcellulose and salts thereof may be used. The vinyl polymer compound is not particularly limited, but examples thereof include polyvinylpyrrolidone. Polyvinyl alcohol (completely or partially saponified), carboxyvinyl polymer and The thickening component of component (A) may be carboxymethyl cellulose, methyl ... Preferred are methyl cellulose, vinyl polymer compounds, and salts thereof. cellulose, sodium carboxymethylcellulose, methylcellulose, polyvinyl Pyrrolidone, carboxyvinyl polymers are more preferred, carboxymethyl cellulose, Sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone K1 7. Polyvinylpyrrolidone K25, Polyvinylpyrrolidone K30, Polyvinylpyrrolidone K90, carboxyvinyl polymer is more preferred, carboxymethyl cellulose, Sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone K25 , Polyvinylpyrrolidone K30, Polyvinylpyrrolidone K90, Carboxyvinyl Polymer is particularly preferred.

[0036] In the present invention, the component (A) may be a polyhydric alcohol. However, propylene glycol, glycerin, mannitol, sorbitol, xylitol, and one or more polyhydric alcohols selected from the group consisting of trehalose, ethylenediaminetetraacetate, and trehalose. It is preferable that

[0037] In the present invention, component (A) is berberine, azulene sulfonic acid, allantoin, sulfur, One or more anti-inflammatory ingredients selected from the group consisting of zinc sulfate, pranoprofen and salts thereof. Among the anti-inflammatory ingredients, berberine sulfate, berberine chloride, azulene sulfone Preferred are sodium acetate, allantoin, zinc sulfate, and pranoprofen.

[0038] In the present invention, component (A) is a decongestant component which is naphazoline and / or its salt. Here, the naphazoline salt is preferably naphazoline hydrochloride. .

[0039] In the present invention, component (A) is an antioxidant component which is dibutylhydroxytoluene. obtain.

[0040] In the present invention, the component (A) is an antibacterial component which is sulfamethoxazole or a salt thereof. Here, the salt of sulfamethoxazole can be sulfamethoxazole sodium. It is preferable that the

[0041] These components (A) may all be used alone or in any combination of two or more. In particular, it is preferable to use two or more kinds in combination. For example, two or more different substances in the same classification can be used, or two different substances in different classifications can be used. For example, it may contain two or more types of polysaccharides, or One or more polysaccharides and one or more vitamins can be selected and combined. Monosaccharides, oils, surfactants, anti-allergy ingredients, preservatives, thickening ingredients, polyhydric alcohols The same applies to other (A) ingredients such as anti-inflammatory ingredients, congestion relief ingredients, antioxidant ingredients, and antibacterial ingredients. be.

[0042] In the ophthalmic composition of the present invention, the content of the component (A) may vary depending on the type of the component (A) and other ingredients. Appropriately set according to the type and content of the ingredient, the purpose of the ophthalmic composition, the formulation form, the method of use, etc. However, the total content of component (A) relative to the total amount of the ophthalmic composition is preferably 0. 0001 w / v% or more, more preferably 0.001 w / v% or more, and even more preferably The concentration is preferably 0.005 w / v% or more, and more preferably 0.01 w / v% or more. The total content of the component (A) is preferably 20 w / v% or less based on the total amount of the composition. More preferably, it is 10 w / v% or less, even more preferably, it is 5 w / v% or less, and particularly preferably It is preferably 3 w / v % or less, and most preferably 1 w / v % or less.

[0043] The total content of polysaccharides in the total amount of the ophthalmic composition of the present invention varies depending on the type of component (A), other ingredients, The amount is appropriately set according to the type and content of the component. Therefore, the total content of polysaccharides in the ophthalmic composition is 0.0001 w / v% to 6 w / v%. It is preferable that the content is 0.0005 w / v% to 4 w / v%. It is particularly preferable that the content be 0.001 w / v % to 2 w / v %.

[0044] In a preferred embodiment, for example, chondroitin sulfate or a salt thereof is used as the chondroitin sulfate salt (A ) component, for example, the content of chondroitin sulfate or its salt alone The content of the ophthalmic composition may be 0.0001 w / v% to 5 w / v% based on the total amount of the ophthalmic composition. It is preferable that the content is 0.0005 w / v% to 3 w / v%, and more preferable that the content is 0.00 It is particularly preferable that the content is 1 w / v% to 1 w / v%. In another embodiment, hyaluronic acid or When the salt is contained as component (A), for example, hyaluronic acid or a salt thereof is contained alone. The content is 0.0001 w / v% to 1 w / v% based on the total amount of the ophthalmic composition. It is preferable that the content is 0.0005 w / v% to 0.5 w / v%. It is particularly preferable that the content be 0.001 w / v % to 0.05 w / v %.

[0045] The total content of monosaccharides in the total amount of the ophthalmic composition of the present invention varies depending on the type of component (A), other ingredients, The amount is appropriately set according to the type and content of the component. Therefore, the total content of monosaccharides in the ophthalmic composition is 0.0001 w / v% to 3 w / v%. It is preferable that the content is 0.005 w / v% to 1.5 w / v%. It is more preferable that the content be 0.001 w / v % to 0.5 w / v %.

[0046] In a preferred embodiment, the component (A) contains, but is not limited to, glucose. In the case where the ophthalmic composition is used, the content of glucose alone is 0.000 based on the total amount of the ophthalmic composition. The content is preferably 1 w / v% to 3 w / v%, and more preferably 0.005 w / v% to 1.5 w / v%. It is more preferable that the content is 0.001 w / v% to 0.5 w / v%. Preferred.

[0047] The total content of vitamins in the total amount of the ophthalmic composition of the present invention varies depending on the type of component (A), other The amount is appropriately set according to the type and amount of the blended components. This makes the effects of the present invention more pronounced. From this viewpoint, the total content of vitamins is 0.00001 w / v of the total amount of the ophthalmic composition. It is preferable that the content is 0.0005 w / v% to 0.8 w / v%. It is more preferable that the content is 0.0005 w / v% to 0.4 w / v%. Particularly preferred.

[0048] In a preferred embodiment, for example, retinol palmitate is used as component (A), but is not limited thereto. When retinol palmitate is contained as a single component in the total ophthalmic composition, The amount is preferably 10 to 500,000 units / 100 mL, and 100 to 300,000 units / 100 mL is more preferable, and 500 to 200,000 units / 100 mL is even more preferable. Depending on the unit of retinol palmitate used, 0.005 to 0.5 W / V% is preferable. Preferably, the range is 0.001 to 0.4 W / V%, more preferably, 0.01 to 0.3 W / V%. Similarly, in another preferred embodiment, for example, cyanocobalamin is used as component (A). When contained as a single component, the content of cyanocobalamin alone shall be 0. It is preferable that the content is 0.00001 w / v% to 1 w / v%, and more preferably 0.00005 w / v% to 0 It is more preferable that the content is 0.5 w / v%, and more preferably 0.0001 w / v% to 0.02 w / v%. It is particularly preferred that it is contained.

[0049] The total content of the oil component in the total amount of the ophthalmic composition of the present invention varies depending on the type of component (A), other components, and the amount of the oil component. The above range is appropriately set depending on the type and content of the component. Therefore, the total content of oil is 0.00001 w / v% to 6 w / v% based on the total amount of the ophthalmic composition. It is preferable that the content is 0.0005 w / v% to 3 w / v%. It is preferable that the content is 0.0001 w / v % to 1 w / v %.

[0050] In a preferred embodiment, for example, sesame oil is contained as component (A), but is not limited thereto. In this case, the content of sesame oil alone is 0.00001 w / v% to 5 w / v% of the total amount of the ophthalmic composition. It is preferable that the content is 0.0001 w / v% to 1 w / v%. Similarly, in another preferred embodiment, for example, castor oil is contained as component (A). When using an ophthalmic composition containing castor oil, the content of castor oil alone shall be 0.00001 w / v of the total amount of the ophthalmic composition. It is preferable that the content is 0.0001 w / v% to 1 w / v%. Similarly, in another preferred embodiment, for example, liquid paraffin is used as (A). When liquid paraffin is contained as a component, the content of liquid paraffin alone is 100% of the total amount of the ophthalmic composition. It is preferable that the content is 0.00001 w / v% to 2 w / v%, and the content is 0.0001 w / v% to It is more preferable that the content is 1 w / v %. Similarly, in another preferred embodiment, e.g. When serine is contained as component (A), the content of petrolatum alone is It is preferable that the content of the agent is 0.00001 w / v% to 5 w / v% of the total amount of the agent, and 0.00005 It is more preferable that the content is from w / v % to 1 w / v %.

[0051] The total content of the surfactants in the total amount of the ophthalmic composition of the present invention depends on the type of component (A), other The amount is appropriately set according to the type and amount of the blended components. This makes the effects of the present invention more pronounced. From this viewpoint, the total content of the surfactant is 0.00001 w / v of the total amount of the ophthalmic composition. It is preferable that the content is 0.0001 w / v% to 8 w / v%. It is more preferable that the content is 0.001 w / v% to 5 w / v%. .

[0052] In a preferred embodiment, for example, polyoxyethylene polyoxypropylene When ethylene glycol is contained as component (A), polyoxyethylene polyoxypropylene The content of pyrene glycol alone is 0.00001 w / v% to the total amount of the ophthalmic composition. It is preferable that the content is 10 w / v%, and it is preferable that the content is 0.001 w / v% to 8 w / v%. It is more preferable that the content is 0.001 w / v% to 5 w / v%. In another preferred embodiment, for example, polyoxyethylene castor oil is contained as component (A). In this case, the content of polyoxyethylene castor oil alone is 0.01% of the total amount of the ophthalmic composition. It is preferable that the content is 0.00001 w / v% to 10 w / v%, and the content is 0.0001 w / v% to It is more preferable that the content is 5 w / v%, and it is more preferable that the content is 0.001 w / v% to 3 w / v%. is particularly preferred.

[0053] In a preferred embodiment, for example, the resistance to the total amount of the ophthalmic composition of the present invention is not limited. From the viewpoint of exhibiting the effect of the present invention more significantly, the total content of allergens is It is preferable that the content of the component is 0.00001 w / v% to 5 w / v% of the total amount of the composition. It is more preferable that the content is 0.0005 w / v% to 1 w / v%, and more preferably 0.0005 w / v% It is particularly preferable that the content is up to 0.5 w / v %.

[0054] In a preferred embodiment, for example, the present invention provides a protection against the total amount of the ophthalmic composition of the present invention, but is not limited thereto. The total content of the rotten components is preferably 100% or more of the total amount of the ophthalmic composition from the viewpoint of more significantly exhibiting the effects of the present invention. It is preferable that the content is 0.0000001 w / v% to 2 w / v%. It is more preferable that the content is 0.00001 w / v% to 1 w / v%, and more preferably 0.00001 w / v% to 1 w / v%. It is particularly preferable that the content be 0.5 w / v%.

[0055] In a preferred embodiment, for example, but not limited to, chlorhexidine, sorbic acid or the like When these salts are contained as component (A), for example, chlorhexidine, sorbic acid or The content of each of these salts alone is 0.00001 w / v relative to the total amount of the ophthalmic composition. It is preferable that the content is 0.00005 w / v% to 1 w / v%. It is more preferable that the content is 0.0001 w / v% to 0.5 w / v%. In another embodiment, for example, polyhexamethylene biguanide or a salt thereof is used as component (A). In the case where the compound contains polyhexamethylene biguanide or a salt thereof, for example, The amount is 0.0000001 w / v% to 0.001 w / v% based on the total amount of the ophthalmic composition. It is preferable that the content is 0.000001 w / v% to 0.0005 w / v%. It is more preferable that the content be 0.00001 w / v% to 0.0001 w / v%. is particularly preferred.

[0056] In a preferred embodiment, for example, the amount of the ophthalmic composition of the present invention is increased by, but not limited to, the total amount of the ophthalmic composition of the present invention. From the viewpoint of more significantly exhibiting the effects of the present invention, the total content of the viscosity component is It is preferable that the content is 0.0001 w / v% to 10 w / v%. It is more preferable that the content is 5 w / v% to 8 w / v%, and more preferably 0.001 w / v% to 5 w / v%. It is particularly preferable that the content is 100%.

[0057] In a preferred embodiment, for example, the amount of the ophthalmic composition of the present invention is not limited to a specific amount. From the viewpoint of more significantly exhibiting the effects of the present invention, the total content of the hydric alcohol is It is preferable that the content of the substance is 0.00005 w / v% to 10 w / v% of the total amount of the substance. It is more preferable that the content is 0.0001 w / v% to 8 w / v%, and more preferably 0.001 w / v% to It is particularly preferable that the content is 5 w / v %.

[0058] In a preferred embodiment, for example, the consumption of the ophthalmic composition of the present invention is not limited to the above. From the viewpoint of more significantly exhibiting the effects of the present invention, the total content of the flame-retarding components is set to be 100% by weight of the total amount of the ophthalmic composition. It is preferable that the content is 0.00001 w / v% to 3 w / v%. It is more preferable that the content is 0.05% to 1.5% by weight / volume, and more preferably 0.0001% to 0.0001% by weight / volume. It is particularly preferable that the content is 0.6 w / v %.

[0059] In a preferred embodiment, for example, the total amount of the ophthalmic composition of the present invention is preferably, but not limited to, From the viewpoint of more significantly exhibiting the effects of the present invention, the total content of the blood removing components is It is preferable that the content is 0.0001 w / v% to 0.1 w / v% of the total amount, and 0. It is more preferable that the content is 0.0005 w / v% to 0.08 w / v%, and more preferably 0.0005 w / v% to 0.08 w / v%. It is particularly preferable that the content be 0.05 w / v%.

[0060] In a preferred embodiment, for example, the resistance to the total amount of the ophthalmic composition of the present invention is not limited. From the viewpoint of more significantly exhibiting the effects of the present invention, the total content of the oxidizing components is It is preferable that the total amount of the component is 0.000001 w / v% to 2 w / v%, and 0.0 It is more preferable that the content is 0.0001 w / v% to 1.5 w / v%, and more preferably 0.0001 w / v% to 1.5 w / v%. It is particularly preferable that the content be 1% to 1 w / v%.

[0061] In a preferred embodiment, for example, the resistance to the total amount of the ophthalmic composition of the present invention is not limited. From the viewpoint of more significantly exhibiting the effects of the present invention, the total content of the bacterial components is set to be 100% by weight of the total amount of the ophthalmic composition. The content is preferably 0.01 w / v% to 6 w / v%, and more preferably 0.05 w / v% It is more preferable that the content is 0.4 w / v% to 4 w / v%. is particularly preferred.

[0062] In this specification, the terpenoids of the component (B) are those having an isoprene unit as a constituent unit. Among the terpenes having the structure, those having functional groups such as carbonyl groups and hydroxyl groups Based on the number of isoprene units, terpenoids are classified as monoterpenoids. (2 isoprene units; C10), sesquiterpenoids (3 isoprene units; C1 5), diterpenoids (4 isoprene units; C20), sesterterpenoids (5 isoprene units; C20) triterpenoids (6 isoprene units; C30), tetraterpenoids (6 isoprene units; C25), triterpenoids (6 isoprene units; C30), They are classified as laterpenoids (8 isoprene units; C40), polyterpenoids, etc.

[0063] Specifically, but not limited to, menthol, menthone, camphor, borneol, geminate, etc. Laniol, cineole, citronellol, carvone, anethole, eugenol, limonol, Examples of the linalool include linalyl acetate, linalyl acetate, and derivatives thereof. These terpenoids may be used in any of the d-, l- or dl-forms. Menthol, menthone, camphor, borneol, geraniol, cineol More preferred are menthol, camphor, borneol and geraniol.

[0064] In the present invention, the essential oil containing the above-mentioned compound is used as a terpenoid. Such essential oils include, for example, eucalyptus oil, bergamot oil, peppermint oil, and Oil, cool mint oil, spearmint oil, peppermint oil, fennel oil, cinnamon oil, rose oil, Camphor oil and the like are preferred. Eucalyptus oil, bergamot oil, and peppermint oil are preferred. These terpenoids can be used alone or in combination of two or more kinds. All of these terpenoids are commercially available.

[0065] In the ophthalmic composition of the present invention, the content of the component (B) depends on the type of the component (B) and other ingredients. Appropriately set according to the type and content of the ingredient, the purpose of the ophthalmic composition, the formulation form, the method of use, etc. In order to more significantly exhibit the effects of the present invention, The total content of the component (B) is preferably 0.00001 w / v% or more, and more preferably or 0.00005 w / v% or more, and more preferably 0.0001 w / v% or more. The content of the component (B) is the total content of the component (B) relative to the total amount of the ophthalmic composition. The concentration is preferably 1 w / v % or less, more preferably 0.5 w / v % or less, and even more preferably It is preferably 0.1 w / v% or less.

[0066] Although not limited thereto, from the viewpoint of exhibiting the effects of the present invention more significantly, the inclusion of the component (B) The amount of the component (B) is 0.00001 w / w based on the total amount of the ophthalmic composition. It is preferable that the content is 0.00005 w / v% to 0.5 w / v%. It is more preferable that the content be 0.0001 w / v% to 0.1 w / v%. More preferred.

[0067] In the ophthalmic composition of the present invention, from the viewpoint of exhibiting the effects of the present invention more significantly, (A The blending ratio of component (B) to component (A) is 1 part by weight of the total content of component (B). The total content of the components is preferably 0.00001 to 2000 parts by weight, and more preferably 0.000 It is preferably 1 to 1000 parts by weight, and more preferably 0.0005 to 500 parts by weight. More preferably, the amount is 0.0001 to 100 parts by weight, and particularly preferably, the amount is 0.001 to 100 parts by weight. Most preferred is 10 parts by weight.

[0068] In this specification, a container molded from a resin containing PBT (PBT-containing resin (also called container) refers to an ophthalmic container made entirely or partially of polybutylene terephthalate. In this case, "a part of the container" refers to the inside of the container. The part that comes into contact with the ophthalmic composition is at least a part of the part that comes into contact with the ophthalmic composition. The part that comes into contact with the container is the innermost layer of the structure consisting of the inner plug, the perforated inner plug, and the inner surface of the container. In containers with a perforated nozzle, only the nozzle portion may contain PBT. Alternatively, the main body portion for containing the ophthalmic composition other than the inner plug may be molded from a resin. The container may be made of a PBT-containing resin. Alternatively, the entire container may be made of a PBT-containing resin. From the viewpoint of effectively suppressing the decrease in the content of terpenoids, etc., It is preferable that the main body portion for containing the ophthalmic composition is molded from a PBT-containing resin. At least a part of the surface that comes into contact with the composition may be made of a PBT-containing resin. From the viewpoint of effectively suppressing the decrease in the content of penoids, etc., the entire surface of the ophthalmic composition that comes into contact with the ophthalmic composition is It is most preferable that a part of the container is made of a PBT-containing resin. In the case where the resin is formed of the above, the type of resin forming the other parts is not particularly limited, but Polyethylene terephthalate (PET), polystyrene (PS), acrylonitrile butadiene ABS, polycarbonate, polyethylene (PE), polypropylene (PP), polymethyl methacrylate, ethylene vinyl acetate copolymer, ethylene vinyl alkoxide The composition contains as a constituent at least one polymer selected from the group consisting of copolymers. It may be included.

[0069] In the present invention, the shape of the PBT-containing resin container and the capacity that can be contained therein are not particularly limited. For example, if it is a container for ordinary eye drops or contact lens solution, the content volume is 0.1 ml to 50 ml, preferably 2 ml to 40 ml, more preferably The container can hold 4 ml to 25 ml. The PBT-containing resin container can be used as an eyewash or If it is a container for contact lens care liquid, it can be between 40ml and 600ml. do.

[0070] In addition, the PBT-containing resin container of the present invention is used for an ophthalmic composition to be applied to a contact lens. The container may be capable of containing the above.

[0071] The ophthalmic composition used in the present invention is a multi-dose type that contains a dose for multiple uses. It may be of a unit dose type that contains a single dose.

[0072] In the present invention, the PBT-containing resin container is particularly an eye drop container, an eyewash container, a contact lens container, etc. Contact lens attachment solution storage container, contact lens care solution storage container (contact lens cleaning solution storage container container for contact lens storage solution, container for contact lens disinfectant solution, Contact lens packaging solution storage containers, etc. In this specification, the term "contact lens" refers to any type of contact lens. Contact lenses are either soft or hard contact lenses. This is also fine.

[0073] The ophthalmic composition of the present invention is contained in a PBT-containing resin container. An ophthalmic composition is contained in a resin container, and the ophthalmic composition is contained in a resin container. A contact lens application product may be provided. Also, a P A BT-containing resin container may be provided.

[0074] The PBT-containing resin in the PBT-containing resin container of the present invention is terephthalic acid or its ester. The copolymer can be obtained by known polymerization methods such as polycondensation of a cyclohexyl-forming derivative with 1,4-butanediol. The polymers include those that can be used in applications where additives such as stabilizers and flame retardants may be added. As the resin, any commercially available PBT resin can be used without any particular restrictions. For example, "Novaduran (registered trademark) 5010R5" by Mitsubishi Engineering Plastics Corporation Terephthalic acid or its ester-forming derivative and 1,4-butanediol The polymers synthesized by polycondensation of the above may contain other monomers as constituents. Other polymers may be included. Examples of the other polymers include polycarbonate, ( Meth)acrylic acid polymer, polystyrene, polyethylene naphthalate, polyarylate , polyethylene terephthalate (PET), polyethylene (PE), polypropylene, etc. Preferably, the PBT-containing resin of the present invention is a polyester resin. Polyether ether is synthesized by polycondensation of dimethyl phthalate or terephthalate with 1,4-butanediol. The polymer is preferably 50% by weight or more, more preferably 60% by weight or more, of the polymer components constituting the resin. % by weight or more, and even more preferably 70% by weight or more. You can also use the following.

[0075] The PBT-containing resin of the present invention further includes resin reinforced with a reinforcing agent such as glass fiber. nothing.

[0076] In the present invention, an ophthalmic composition containing the component (A) and the component (B) is By storing the product in a container where some or all of the contact surface is made of resin containing PBT, This provides a method for suppressing the decrease in the content of terpenoids, which are the component (B). In the present invention, a part or the whole of the surface that comes into contact with the ophthalmic composition is molded from a resin containing PBT. The ophthalmic composition containing the component (A) and the component (B) is added to the ophthalmic composition contained in the container. The present invention provides a method for imparting an effect of suppressing a decrease in the content of terpenoids, which are a component of fermentation. Due to the effect of the above, terpenoids may be adsorbed by the resin that makes up the container, and other factors may cause It is possible to suppress the decrease in content due to

[0077] In the present invention, the suppression of a decrease in the content of terpenoids means that the ophthalmic composition is prepared by The terpenoid content was compared with that immediately after use and storage for a certain period of time. It is sufficient to suppress the change in the content of steroids.

[0078] Furthermore, in the present invention, the component (A) and the component (B) are present together in the ophthalmic composition, A container in which a part or all of the surface that comes into contact with the ophthalmic composition is molded from a resin containing PBT. By storing the composition in a container, a method of imparting an odor suppressing effect to the ophthalmic composition is provided. The effects of the present invention are that the deterioration of the fragrance of the ophthalmic composition after use or storage is suppressed, and the odor is eliminated. In one embodiment, the present invention provides an ophthalmic composition comprising: ) and component (B) are present together, and a part or all of the surface that comes into contact with the ophthalmic composition is P By storing the ophthalmic composition in a container molded from a resin containing BT, the terpene in the composition can be easily obtained. It is also possible to provide a method for imparting an effect of suppressing deterioration of the aroma of phenols.

[0079] In the present invention, the odor of the ophthalmic composition is suppressed or the deterioration of the scent of terpenoids is suppressed. The control is compared with the odor and the scent of terpenoids immediately after the preparation of the ophthalmic composition. This helps to suppress the generation of these odors or prevent changes in scent even after a certain period of use or storage. It is sufficient if the amount of such information is kept under control.

[0080] The ophthalmic composition of the present invention contains a buffer in addition to the components (A) and (B). This makes it possible to adjust the pH of the ophthalmic composition, and the effects of the present invention are more pronounced. As the buffering agent, any buffer that is physiologically or pharma- ceutical acceptable may be used without restriction. Examples of suitable buffers include, but are not limited to, citrate buffer, acetate buffer, tris buffer, carbonate buffer, borate buffer, and lysine buffer. Any of the above buffers can be used. The buffering agent may be used alone or in any combination of two or more kinds. Specifically, citric acid or a salt thereof, acetic acid or a salt thereof, tris(hydroxymethyl)amino Methane (Trometamol), carbonic acid or its salts, boric acid or its salts, and phosphoric acid or its salts. Among these buffering agents, citric acid or its salts, trishydroxybutyric acid, Methylaminomethane, boric acid or its salts, phosphoric acid or its salts, epsilon-amino Protic acid is preferred, boric acid or a salt thereof, phosphoric acid or a salt thereof, epsilon-amino caprylic acid is preferred, Proic acid is more preferred.

[0081] In the ophthalmic composition of the present invention, the content of the buffering agent varies depending on the type of the buffering agent and the types of other blended ingredients. The type and content are appropriately determined depending on the application, formulation form, method of use, etc. of the ophthalmic composition. In order to more significantly exhibit the effects of the present invention, the amount of the buffer is The total content is preferably 0.001 w / v% or more, more preferably 0.01 w / v% or more. % or more, more preferably 0.05 w / v% or more, and even more preferably 0.1 w / v% or more. The total content of the buffer is preferably 1 / v% or more based on the total amount of the ophthalmic composition. is 15 w / v% or less, more preferably 10 w / v% or less, and even more preferably 7.5 % w / v or less, and even more preferably 5% w / v or less.

[0082] Although not limited, the content of the buffering agent is, as the total amount of the buffering agent, based on the total amount of the ophthalmic composition. The preferred range is 0.001 to 15 w / v%, and more preferably 0.01 to 10 w / v. % by weight, more preferably 0.05 to 7.5 w / v%, and even more preferably The concentration is 0.1 to 5 w / v%.

[0083] In the ophthalmic composition of the present invention, in addition to the components (A) and (B), It is preferable to include other components that can be used in the manufacture of the product. Such components are not particularly limited. However, from the viewpoint of more significantly exhibiting the effects of the present invention, sodium edetate is particularly preferred. In the present invention, sodium edetate is available as a commercially available product. It is also possible.

[0084] In the ophthalmic composition of the present invention, from the viewpoint of exhibiting the effects of the present invention more significantly, The total content of sodium edetate in the total amount of the composition is preferably 0.0001 w / v % or more, more preferably 0.0005 w / v% or more, and even more preferably 0.0 The total content of sodium edetate in the ophthalmic composition is 0.1 w / v% or more. is preferably 1 w / v % or less, more preferably 0.5 w / v % or less, and even more preferably or 0.2 w / v% or less. (A) Ratio of sodium edetate content to the component The ratio is 1 part by weight of the total content of component (A) and 0.0 parts by weight of the total content of sodium edetate. 0.001 to 1000 parts by weight is preferable, 0.0005 to 500 parts by weight is more preferable, 0. It is even more preferable that the amount is 001 to 200 parts by weight.

[0085] In the ophthalmic composition of the present invention, in addition to the components (A) and (B), Other ingredients that can be used in the manufacture of the present invention may be included. Such ingredients are not particularly limited. For example, the 2012 edition of the General Drug Manufacturing (Import) Approval Standards (Regular Drugs) Examples of active ingredients in ophthalmic drugs listed in the Ophthalmic Drugs for Eye Diseases (supervised by the Japan Eye Care Science Society) are listed below. Specifically, the ingredients include the following:

[0086] Antihistamines: chlorpheniramine maleate, etc. Antiallergic drugs: ashitazanolast, amlexanox, ibudilast, levocaba hydrochloride statin, sodium cromoglycate, pemirolast potassium, olopatadine hydrochloride, etc. Decongestants: Tetrahydrozoline hydrochloride, epinephrine, epinephrine hydrochloride, ef ephedrine, phenylephrine hydrochloride, methylephedrine hydrochloride, etc. Amino acids: Potassium aspartate, magnesium aspartate, aminoethyls Sulfonic acid, etc. Anti-inflammatory agents: dipotassium glycyrrhizinate, lysozyme chloride, bromfenac, ketorolac Tromethamine, nepafenac and the like. Astringents: zinc oxide, zinc lactate, etc. Others: Sulfisoxazole, Sulfisomidine sodium, Neostigmine methylsulfate Min et al.

[0087] In addition, the ophthalmic composition of the present invention may further include a carrier, a thickener, a preservative, a pH adjuster, and a general Additives such as isotonic agents and chelating agents are appropriately selected and used in appropriate amounts in combination of one or more. For example, the following additives may be included in the Pharmaceutical Additives Encyclopedia 2007 (Japanese Examples of additives are listed in the "Additives for Food Additives" (Edited by the Japan Pharmaceutical Additives Association). Additives are included. Carrier: Aqueous carrier such as water or aqueous ethanol. Thickener: Hydroxypropyl methylcellulose, polyvinyl alcohol, hydroxyethyl Chilled cellulose, xanthan gum, etc. Chlorhexidine, sorbic acid, polyhexamethylene biguanide, sulfamethoxazo Preservatives, bactericides or antibacterial agents, excluding alkylpolyaminoethyl chloride and their salts: Glycine, sodium benzoate, ethanol, tyloxapol, benzalkonium chloride , benzethonium chloride, chlorobutanol, sodium dehydroacetate, paraoxybenzoic acid Methyl parahydroxybenzoate, Ethyl parahydroxybenzoate, Propyl parahydroxybenzoate, Parahydroxybenzoic acid Butyl acetate, phenethyl alcohol, oxyquinoline sulfate, benzyl alcohol, polychlorinated Dolonium, chlorcresol, parachlormetaxylenol, etc. Isotonicity agents: Polyethylene glycol, sodium bisulfite, sodium sulfite, chloride Potassium chloride, calcium chloride, sodium chloride, magnesium chloride, etc. pH adjusters: Hydrochloric acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide Magnesium, triethanolamine, monoethanolamine, diisopropanolamine etc. Stabilizers: Butyl hydroxyanisole, sodium formaldehyde sulfoxylate Rongalite, tocopherol, sodium pyrosulfite, monoethanolamine, Aluminum monostearate, glyceryl monostearate, cyclodextrin, dextran Kistran et al. Chelating agents: Ascorbic acid, tetrasodium edetate, succinic acid, trihydroxymethy Aminomethane, Nitrilotriacetic acid, 1-hydroxyethane 1-,1-diphosphonic acid, Phosphoric acid, metaphosphoric acid, hexametaphosphoric acid, etc.

[0088] When water is used as a carrier, the content of water is determined depending on the types and contents of the blended components and the use of the ophthalmic composition. The amount is appropriately determined depending on the purpose, formulation form, method of use, etc., but for example, The water content is 30 w / v% or more, preferably 50 w / v% or more, more preferably 7 0 w / v% or more, more preferably 85 w / v% or more, even more preferably 90 w / v% or more. v% or more.

[0089] The water used in the ophthalmic composition of the present invention may be any water that is physiologically or pharma- ceutical acceptable. Examples of such water include distilled water, tap water, purified water, sterile purified water, water for injection, and These definitions are based on the 16th revised edition of the Japanese Pharmacopoeia. Ku.

[0090] In the present invention, the term "salt" refers to an inorganic salt such as an alkali metal salt or an alkaline earth metal salt. There are basic salts such as salts with bases and salts with organic bases, etc., and sodium, potassium, calcium , magnesium, ammonium, or salts with diethanolamine, ethylenediamine, etc. These salts include, for example, sulfate groups and carboxy groups present in liranaftate, etc. The aryl group can be converted into a salt by a known method. amine, dimethylamine, trimethylamine, dicyclohexylamine, tris(hydroxylamine), dimethyl)aminomethane, N,N-bis(hydroxyethyl)piperazine, 2-amino- 2-Methyl-1-propanol, ethanolamine, N-methylglucamine, L-glucamine salts of amines such as lysine, δ-hydroxylysine, arginine, etc.; or salts of basic amino acids such as lysine, δ-hydroxylysine, arginine, etc. In the present invention, the term "salt" includes acid salts, for example. salts with inorganic acids such as salts of mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; methane sulfonic acid, benzenesulfonic acid, paratoluenesulfonic acid, acetic acid, propionic acid, tartaric acid , fumaric acid, maleic acid, malic acid, oxalic acid, succinic acid, citric acid, benzoic acid, mandelic acid acid, cinnamic acid, lactic acid, glycolic acid, glucuronic acid, ascorbic acid, nicotinic acid, Salts with organic acids such as licylic acid, gluconic acid, palmitic acid, etc.; or aspartic acid, glutamine Also included are salts with acidic amino acids such as carboxylic acids.

[0091] The term "physiologically or pharma- ceutically acceptable salt" as used herein includes solvates or hydrates of salts. It may include.

[0092] In the present specification, the form of the ophthalmic composition may be any form containing water, for example. The composition may be in the form of an aqueous solution, a gel, a suspension, or an emulsion, and is preferably in the form of an aqueous solution. be.

[0093] The pH of the ophthalmic composition of the present invention is not limited as long as it is within a physiologically or pharma- ceutical acceptable range. However, for example, the pH is 3 or more, preferably 4 or more, more preferably 5 or more, and More preferably, the pH is 5.5 or more, and even more preferably, the pH is 6 or more. Preferably, it is 8.5 or less, more preferably, it is 8 or less, even more preferably, it is 7.5 or less, and even more preferably, it is 8 or less. More preferably, it is 7 or less.

[0094] The osmotic pressure ratio of the ophthalmic composition of the present invention is within a physiologically or pharma- ceutical acceptable range. The composition may be appropriately selected depending on the type and content of the ingredients, the purpose of the ophthalmic composition, the formulation form, the method of use, etc. For example, it is set to 0.4 to 5, preferably 0.5 to 4, and more preferably 0.6 to 5. The ophthalmic composition of the present invention may be used in an amount of from 0.3 to 1.0, more preferably from 0.7 to 2. The osmolality ratio is based on the osmolality measurement method (osmolar concentration measurement method) of the 16th revised Japanese Pharmacopoeia. The osmotic pressure is calculated as the ratio to that of physiological saline.

[0095] The viscosity of the ophthalmic composition of the present invention may be adjusted as desired so long as it is within a physiologically or pharma- ceutical acceptable range. The composition may be appropriately determined depending on the type and content of the compound, the purpose of the ophthalmic composition, the formulation form, the method of use, etc. Rotational viscometer (RE550 type viscometer, manufactured by Toki Sangyo Co., Ltd., rotor: 1°34'×R 24) The viscosity at 20°C measured is preferably 0.01 to 10,000 mPa·s. Preferably, the viscosity is 0.05 to 8000 mPa·s, and more preferably, the viscosity is 0.1 to 6000 mPa·s. It is more preferable to set it to Pa·s.

[0096] The method of using the ophthalmic composition of the present invention is based on the types and contents of the blended components, the use of the ophthalmic composition, and The dosage form is appropriately determined depending on the use and formulation.

[0097] The ophthalmic composition of the present invention can be produced by a known method. It can be manufactured using the method described in the General Provisions of Preparations in the Japanese Pharmacopoeia. A sterilization step may be included.

[0098] The ophthalmic composition of the present invention, either alone or in the form of a kit, is contained in a PBT-containing resin container. The PBT-containing resin container is provided to accommodate the ophthalmic composition of the present invention therein. By doing so, it is possible to suppress the decrease in the terpenoid content and maintain it in a good condition.

[0099] Specific embodiments of the ophthalmic composition of the present invention include, but are not limited to, eye drops (ophthalmic solutions or Eye drops), contact lens eye drops, artificial tears, eyewash (same as eyewash or eyewash) (ii), eyewash for contact lenses, contact lens wearing solution, contact lens care products The ophthalmic composition of the present invention includes an eye ointment and the like (including disinfectants, preservatives, detergents, etc.). , and the decrease in the content of terpenoids can be suppressed. It is particularly suitable for use in eye drops and contact lens drops. It is preferably used in eye preparations.

[0100] The ophthalmic composition of the present invention is capable of suppressing a decrease in the content of terpenoids, and therefore is In addition, the ophthalmic composition of the present invention is It is possible to suppress the deterioration of the aroma of lupenoids and to suppress odor. The composition is contained in a butylene terephthalate-containing resin container and contains components (A) and (B). It is possible to provide a fragrance sustaining agent that

[0101] In another embodiment, the present invention provides an ophthalmic composition comprising component (A) and component (B). The object is provided with a surface, which is in contact with the ophthalmic composition, partially or entirely containing polybutylene terephthalate. The container may be a container containing an ophthalmic composition, the container being made of a resin molded to have a shape similar to that of the ophthalmic composition.

[0102] In another embodiment, the present invention provides an ophthalmic composition comprising component (A) and component (B). A part or the whole of the surface that comes into contact with the ophthalmic composition for containing an object is made of polybutylene terephthalate. The container may be made of a resin containing talc.

[0103] In another embodiment, the present invention provides an ophthalmic composition comprising component (A) and component (B). A product, the surface of which comes into contact with the ophthalmic composition being partly or entirely made of polybutylene terephthalate. The present invention can be a method for producing an ophthalmic composition, the ophthalmic composition being contained in a container molded from a resin containing . EXAMPLES

[0104] The present invention will now be described in detail with reference to examples, but the present invention is not limited to the following examples. It's not something like that.

[0105] (Preparation of test solution) Ophthalmic compositions having the compositions shown in Tables 1 and 2 were prepared by a conventional method. Sodium hyaluronate (weight average molecular weight 850,000 to 1.6 million), sodium chondroitin sulfate (B) menthol (weight average molecular weight 24,000 to 34,000) or glucose, The borax, boric acid, and borax were dissolved in purified water at about 70°C with stirring, and the respective solutions were added to the amounts shown in Tables 2 to 3. The ophthalmic composition was prepared to have a concentration of 0.01g / mL. The pH of the composition was measured using a HORIBA pH meter. The measurements were carried out at room temperature.

[0106] [Table 1]

[0107] [Table 2]

[0108] (Test Example 1. Evaluation test of l-menthol residual rate) The test solutions of Examples 1 to 3 and Comparative Examples 1 to 8 were placed in 10 mL transparent glass vials (Septa The size of the tubes was approximately 1 cm in diameter and 2.0 mm in thickness. PBT-containing resin (product name: PBT Natural, manufactured by Aram Co., Ltd.) or hard PE resin (product name Each piece was immersed in a plastic bag (hard polyethylene, manufactured by Aram Co.) and quickly sealed. After heat treatment at 60℃ for one week, the solution was analyzed by HPLC under the following conditions. The residual amount of l-menthol in it was quantified. This heat treatment corresponds to the case of storage at room temperature for about 3 years. Using the value of the quantified l-menthol immediately after the preparation of each test solution in the same manner, the l-menthol residual ratio (%) was determined according to the following formula.

[0109] <HPLC measurement conditions> Detector: Differential refractometer (cell temperature: constant temperature near 40 °C) Column: YMC-Pack C8 (inner diameter 4.6 mm, length 15 cm, particle size 5 μm) Column temperature: 40 °C Mobile phase: water / acetonitrile mixture (1:1) Flow rate: Adjusted so that the retention time of menthol is about 8 minutes Injection volume: 100 μL

[0110] l-menthol residual ratio (%) = l-menthol concentration after heat treatment / l-menthol concentration immediately after the preparation of each test solution × 100

[0111] As shown in Table 1 and Figure 1, in the heat-treated product with only a glass container (Comparative Example 1), the l-menthol residual ratio decreased to 81.7%. In Comparative Examples 2 and 3 in which the PBT-containing resin or the rigid PE resin was immersed, the residual ratio of l-menthol further decreased, and it was found that the residual ratio of l-menthol was also deteriorated in the PBT-containing resin compared with Comparative Example 1.

[0112] On the other hand, in Example 1 to which sodium hyaluronate was added, it was confirmed that the l-menthol residual ratio was improved. Furthermore, in Comparative Example 4 in which the rigid PE resin was immersed in the test solution containing sodium hyaluronate, it was also confirmed that the l-menthol residual ratio did not improve significantly.

[0113] ​​​​​​​​As shown in Table 2 and Figure 2, the results of the experiments using sodium chondroitin sulfate or glucose were In Example 2 or 3, it was confirmed that the residual rate of l-menthol was improved.

[0114] (Test Example 2. Sensory Evaluation Test 1) The ophthalmic compositions of Example 4 and Comparative Examples 9 to 11 shown in Table 3 were prepared, and the sensory properties of each test solution were evaluated. Specifically, the ophthalmic compositions of Example 4 and Comparative Examples 9 to 11 were poured into 10 mL transparent Glass vials (septum caps) were filled with 3 mL of solution. PBT-containing resin with a size of approximately 2.0 mm (product name: PBT Natural, manufactured by Aram Co., Ltd.) Each piece was soaked in hard PE resin (product name: hard polyethylene, manufactured by Aram Co., Ltd.) and quickly The container was then sealed in a thermostatic chamber. The container was then heat-treated at 60°C for one week. 30 μL of the test liquid was dropped onto the arm, spread in a circle of about 2 cm in diameter with the finger, and the odor was smelled. The results were evaluated using the Visual Analog Scale. Regarding the "scent that can be felt" and "good scent," the subjects were asked to answer "not smelling it at all" at both ends of a 10 cm line. "I can smell it very much" is 0mm, and "I can smell it very much" is 100mm. The subject was asked to indicate a point on the line. The distance (mm) from the 0mm point was measured and the sensory score was calculated. In addition, "I can't smell anything at all" was rated as 0 mm, and "I can't stand the unpleasant smell" was rated as 1 mm. The subject was asked to indicate a point on the line that corresponded to the odor of each test liquid, and the The distance (mm) from the point was measured and used as the odor score. The experiment was conducted by five selected subjects. The results are shown in Table 3.

[0115] [Table 3]

[0116] As shown in Table 3, sodium chondroitin sulfate was added to the resin containing PBT. Example 4 is the same as Comparative Example 9, which does not contain sodium chondroitin sulfate, and hard PE resin. In comparison with Comparative Example 11, the sensory sense of l-menthol and the sensory sense of a pleasant fragrant smell were stronger. The results were very good. Furthermore, there was little odor after heat treatment, and the sensory quality was good. Comparative Example 10, which did not contain sodium droitin sulfate but contained xanthan gum, was Even when the resin was immersed, the functionality was poor.

[0117] (Test Example 3. Sensory Evaluation Test 2) Ophthalmic compositions of Examples 5 to 8 and Comparative Examples 12 to 15 shown in Table 4 were prepared, and the sensory properties of each test solution were evaluated. Specifically, the product was heat-treated in the same manner as in Test Example 2, and the odor was measured using the VAS method. The evaluation was made based on the following criteria: "Aromatic scent" was evaluated based on the following criteria: "Not at all" at both ends of a 10 cm straight line. "Not noticeable" is 0mm, and "Strongly noticeable" is 100mm, and the intensity of the odor of each test liquid is measured. The subjects were asked to indicate a point on the line that corresponded to the aroma before and after heat treatment. The fragrance is evaluated based on the criteria of "not altered" being 0mm and "altered" being 100mm. The test was conducted on three subjects who were sensitive to smells. The results are shown in Table 4.

[0118] [Table 4]

[0119] As shown in Table 4, PBT-containing resin was immersed in each test solution containing component (B) and component (A). The fragrance after heat treatment in Examples 5 to 8, which were immersed in hard PE resin, was superior to that in Comparative Examples 12 to 15, which were immersed in hard PE resin. Furthermore, Examples 5 and 6 were superior to Comparative Examples 12 and 13 in that the deterioration of the flavor was minimal and the sensory quality was good. The sensory characteristics of the product after heat treatment were excellent, with a pleasant fragrant smell.

[0120] (Test Example 4. Sensory Evaluation Test 3) Ophthalmic compositions of Examples 9 to 29 and Comparative Examples 16 to 36 shown in Tables 5 to 11 were prepared, and The sensory evaluation of each test solution was carried out in the same manner as in Example 2. Specifically, Examples 9 to 29 and Comparative Example 16 ~36 ophthalmic compositions were placed in 10 mL transparent glass vials (septum caps) in 3 portions. In addition, a PBT-containing resin tube measuring approximately 1 cm in diameter and 2.0 mm in thickness was filled into the chamber. (Product name: PBT Natural, manufactured by Aram Co., Ltd.) or hard PE resin (Product name: Hard polyethylene The pieces were then immersed in a thermostatic chamber at 60°C for one week ( Only the test solutions in Table 7 were subjected to heat treatment at 60°C for 3 days. 30 μL of the test solution was dropped onto the arm, spread with the finger in a circle of about 2 cm in diameter, and the odor was smelled and the VAS method was used. In other words, the "refreshing, cool scent" was evaluated by measuring the distance between both ends of a 10 cm straight line. In the test, "not at all" is 0mm, and "very much" is 100mm. The subjects were asked to indicate a point on the line that corresponded to the size of the odor. The odor was measured and used as a sensory score. The point at which the odor of each test liquid is detected is defined as 100 mm, and a point on the line corresponding to the odor of each test liquid is drawn. The subjects were asked to show the odor and the distance (mm) from the 0 mm point was measured and used as the odor score. The latter test was conducted on five subjects who were sensitive to odors. The results are shown in Tables 5 to 11.

[0121] [Table 5]

[0122] As shown in Table 5, the component (A) contains sodium chondroitin sulfate and PBT The example in which the resin containing l-menthol was immersed had a higher l-menthol content than the comparative example in which the resin was immersed in hard PE resin. Furthermore, after the heat treatment, there was little odor and the sensory evaluation was good.

[0123] [Table 6]

[0124] [Table 7]

[0125] [Table 8]

[0126] As shown in Tables 6 to 8, the component (A) contains various vitamins and is a PBT-containing resin. The embodiment in which the hard PE resin was immersed had a higher functional value of l-menthol than the comparative example in which the hard PE resin was immersed. Furthermore, there was little odor after the heat treatment, and the sensory quality was good.

[0127] [Table 9]

[0128] [Table 10]

[0129] As shown in Tables 9 to 10, the oil content of component (A) is vegetable oil, and the PBT-containing resin is The example in which the resin was immersed had a stronger menthol function than the comparative example in which the resin was immersed in hard PE resin. The results were very good. Furthermore, the odor after heat treatment was minimal and the sensory quality was good. The oil component of the resin is mineral oil, and the example in which the PBT-containing resin is immersed is a hard PE resin. Compared to the comparative example in which the oil was soaked, the sensation of l-menthol was very good. There was little odor after the treatment and the sensory sensation was good.

[0130] [Table 11]

[0131] As shown in Table 11, the surfactant was included as component (A) and the PBT-containing resin was immersed in the solution. The embodiment shows a much better function of l-menthol than the comparative example in which hard PE resin was immersed. Furthermore, there was little odor after the heat treatment, and the sensory quality was good.

[0132] (Test Example 5. Sensory Evaluation Test 4) The ophthalmic compositions of Examples 30 to 64 and Comparative Examples 37 to 71 shown in Tables 12 to 27 were prepared and tested. The sensory evaluation of each test solution was performed in the same manner as in Experimental Example 2. Specifically, Examples 30 to 64 and Comparative Example The ophthalmic compositions of Examples 37 to 71 were placed in 10 mL transparent glass vials (with septum caps). In addition, 2 mL of PBT-containing tubes with a diameter of approximately 1 cm and a thickness of approximately 2.0 mm were filled into each tube. Plastic resin (product name: PBT Natural, manufactured by Aram Co., Ltd.) or hard PE resin (product name: hard poly Each piece was immersed in ethylene (manufactured by Aram Co.) and promptly sealed. 14, 15, 16, 17, 20, 21, 22, 23 and Table 27 are stored at 60℃ for 12 days. For Tables 13 and 19, leave at 75°C for 3 days, or for Tables 18, 24, and For the samples in Table 5 and Table 26, a heat treatment was performed by leaving them at 50°C for 12 days. Each test solution was dropped onto the arm in an amount of 30 μL, spread over a circle of about 2 cm in diameter with the fingers, and the odor was smelled. The evaluation was carried out by the method of measuring the "refreshing and cool scent" using a 10 cm straight line. At both ends, "not at all" is 0mm and "very much" is 100mm, and each test The subjects were asked to indicate a point on the line that corresponded to the strength of the liquid's odor. The odor was measured and scored as a sensory score. The point on the line corresponding to the odor of each test liquid is set to 100 mm. The subjects were asked to indicate the dots, and the distance (mm) from the 0 mm dot was measured and used as the odor score. The post-treatment test was carried out on five subjects who were sensitive to odors. Regarding the "deteriorated aroma," the aroma before heat treatment was used as the standard to determine whether the aroma was "not deteriorated." The evaluation was made with "deteriorated" being 100 mm and "altered" being 100 mm. The results are shown in Tables 12 to 27.

[0133] [Table 12]

[0134] [Table 13]

[0135] As shown in Tables 12 and 13, various polysaccharides were included as component (A) and PBT-containing resin was used. The example in which the resin was immersed had a stronger menthol function than the comparative example in which the resin was immersed in hard PE resin. Furthermore, there was little odor after the heat treatment, and the sensory quality was good.

[0136] [Table 14]

[0137] As shown in Table 14, the (A) component contains various vitamins and PBT-containing resin. The example in which the resin was immersed had a stronger menthol function than the comparative example in which the resin was immersed in hard PE resin. Furthermore, there was little odor after the heat treatment, and the sensory quality was good.

[0138] [Table 15]

[0139] As shown in Table 15, various oils were included as component (A), and PBT-containing resin was immersed in the oil. In the embodiment, the functionality of l-menthol is significantly enhanced compared to the comparative example in which hard PE resin was immersed. Furthermore, there was little odor or altered aroma after the heat treatment, and the sensory quality was good.

[0140] [Table 16]

[0141] As shown in Table 16, various surfactants were included as component (A) and PBT-containing resin was used. The embodiment in which the resin was immersed had a higher content of l-menthol and eucalyptus than the comparative example in which the resin was immersed in hard PE resin. The sensory properties of terpenoids such as bergamot oil and bergamot oil were excellent. There was little odor or changed scent, and the sensory sensation was good.

[0142] [Table 17]

[0143] [Table 18]

[0144] [Table 19]

[0145] As shown in Tables 17 to 19, various anti-allergic ingredients are contained as component (A), and PB The example in which the T-containing resin was immersed had a higher l-menthol content than the comparative example in which the hard PE resin was immersed. The sensory properties of terpenoids such as d-camphor and d-camphor were excellent. The odor and the smell of the food were less, and the sensory quality was good. In the example in which both the rubber component and the thickening component were contained and the PBT-containing resin was immersed, the terpenoid The sensory properties of the flavors were very good, and there was little odor or altered aroma after heat treatment.

[0146] [Table 20]

[0147] As shown in Table 20, component (A) contains various preservatives and is used to soak PBT-containing resin. The example in which the hard PE resin was immersed had a significantly lower menthol content than the comparative example in which the hard PE resin was immersed. Furthermore, there was little odor after heat treatment and the sensory quality was good.

[0148] [Table 21]

[0149] As shown in Table 21, various thickening components were included as component (A) and the PBT-containing resin was soaked in the mixture. The example in which the hard PE resin was immersed had a significantly lower menthol content than the comparative example in which the hard PE resin was immersed. Furthermore, there was little odor after heat treatment and the sensory quality was good.

[0150] [Table 22]

[0151] As shown in Table 22, various polyhydric alcohols are contained as component (A), and PBT-containing resins are used. The embodiment in which the oil was immersed had a higher functional value of l-menthol than the comparative example in which the hard PE resin was immersed. Furthermore, there was little odor after heat treatment and the sensory quality was good.

[0152] [Table 23]

[0153] [Table 24]

[0154] As shown in Tables 23 and 24, various anti-inflammatory ingredients are contained as component (A), and the PBT-containing resin is The embodiment in which the oil was immersed had a higher functional value of l-menthol than the comparative example in which the hard PE resin was immersed. Furthermore, there was little odor after heat treatment and the sensory quality was good.

[0155] [Table 25]

[0156] As shown in Table 25, the (A) component contains a congestion relief component and is soaked in a PBT-containing resin. The embodiment in which the hard PE resin was soaked had a much stronger effect of l-menthol than the comparative example in which the hard PE resin was soaked. Furthermore, there was little odor after the heat treatment, and the sensory quality was good.

[0157] [Table 26]

[0158] As shown in Table 26, the (A) component contains an antioxidant component, and the PBT-containing resin is immersed in the component. In the embodiment, the functionality of l-menthol is significantly enhanced compared to the comparative example in which hard PE resin was immersed. Furthermore, there was little odor after the heat treatment, and the sensory quality was good.

[0159] [Table 27]

[0160] As shown in Table 27, the component (A) contains an antibacterial component, and the PBT-containing resin is immersed in the component. The embodiment shows a much better function of l-menthol than the comparative example in which hard PE resin was immersed. Furthermore, there was little odor after the heat treatment, and the sensory quality was good.

[0161] (Preparation of ophthalmic composition and container packaging example) The following ophthalmic compositions are prepared. The units of values ​​in the formulation examples are "w / v%". Formulation 2 , 3, 6, 9, and 10 are filled into the main body of a PET-containing resin container, and P is inserted into the opening of the main body. A BT-containing resin perforated stopper was attached, and a PP-containing resin lid was placed over the container. Fill the container body made of P-containing resin, and place a perforated stopper made of PBT-containing resin on the opening of the container body. The preparations 1 and 11 were each mixed with ethylene vinyl acetate copolymer. The container body is filled with PBT-containing resin, and a perforated stopper made of PBT-containing resin is inserted into the opening of the container body. The container was then fitted with a PE-containing resin lid. Formulations 5 and 8 were filled into the PE-containing resin container body. Then, attach a perforated plug made of PBT-containing resin to the opening of the main body, and close the lid made of PS-containing resin. In these container examples, formulations 1 to 12 are and comes into contact with PBT-containing resin.

[0162]

Table 28

[0163]

Table 29

[0164]

Table 30

Claims

[Claim 1] (A) Polysaccharides; Monosaccharides; Vitamin B １２ Vitamin B ２ one or more vitamins selected from the group consisting of vitamin A, vitamin A group, and panthenol; one or more oils selected from the group consisting of vegetable oils, animal oils, and mineral oils; one or more surfactants selected from the group consisting of polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, and polyoxyl stearate; one or more anti-allergic ingredients selected from the group consisting of tranilast, ketotifen, diphenhydramine, and salts thereof; one or more antioxidants selected from the group consisting of chlorhexidine, sorbic acid, polyhexamethylene biguanide, and salts thereof. An ophthalmic composition comprising one or more components selected from the group consisting of one or more preservative components; one or more thickening components selected from the group consisting of carboxymethylcellulose, methylcellulose, vinyl polymer compounds, and salts thereof; polyhydric alcohols; one or more anti-inflammatory components selected from the group consisting of berberine, azulene sulfonic acid, allantoin, zinc sulfate, pranoprofen, and salts thereof; a congestion relief component which is naphazoline and / or a salt thereof; an antioxidant component which is dibutylhydroxytoluene; and an antibacterial component which is sulfamethoxazole and / or a salt thereof; and (B) a terpenoid, The ophthalmic composition is contained in a container, the surface of which that comes into contact with the ophthalmic composition is partly or entirely made of a resin containing polybutylene terephthalate.

Images